Hepatitis B Annual
Home

Current Issue  

Back Issues   

Instructions   

Search Login    Users online: 262 Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
>>> Ahead of Print <<<
REVIEW ARTICLE
Year : 2010  |  Volume : 7  |  Issue : 1  |  Page : 73-85

HBV therapeutic end points


Chief of Hepatology Services, Sir Ganga Ram Hospital, New Delhi, India

Correspondence Address:
Anil Arora
Chief of Hepatology Services, Sir Ganga Ram Hospital, New Delhi - 110060
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0972-9747.162150

Rights and Permissions

Chronic hepatitis B [CHB] is a major health problem especially in developing countries. Defining the end point of therapy is a key issue in management of CHB patients, since a judicious balance has to be maintained between containing the virus and its sequelae and futility of continuation of therapy beyond a point. The major goals of antiviral therapy are to prevent the complications of CHB such as the development of liver cirrhosis, liver failure, HCC and death. Major advances have been made in the treatment of chronic hepatitis B, which led to significant improvements in the management of the disease. Several virologic end points have been used to evaluate the efficacy of therapy, including HBsAg loss, HBeAg seroconversion and HBV DNA undetectability. It was shown that viral suppression induced by antiviral therapy is a major treatment end point because it is associated with an improvement in liver histology and clinical outcome, and is now achievable in the majority of patients. New end points for the treatment of chronic HBV infection are emerging in the light development of more potent drugs and availability of more sensitive assays with the quantification and kinetics of serum HBsAg, intrahepatic cccDNA and analysis of specific immunological responses. However, liver biopsy still remains the gold standard but is impractical due to invasive nature, sampling error, and the significantly delay it takes for changes to appear. There is no ideal endpoindr for evaluation of therapies for hepatitis B at the moment, and future research should be directed at development and validation of endpoints that could precisely foretell or reflect outcomes in patients with CHB.This review which discusses the various end points of treatment of CHB should be of immense benefit to the practicing clinicians.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1760    
    Printed120    
    Emailed0    
    PDF Downloaded74    
    Comments [Add]    

Recommend this journal